Racial Differences in Clinical Outcomes for Metastatic Renal Cell Carcinoma Patients Treated With Immune-Checkpoint Blockade

Racial Differences in Clinical Outcomes for Metastatic Renal Cell Carcinoma Patients Treated With Immune-Checkpoint Blockade

BackgroundImmune-checkpoint-inhibitors (ICIs) have become the cornerstone of metastatic renal-cell-carcinoma (mRCC) therapy. However, data are limited regarding clinical outcomes by race. In this study, we compared the real-world outcomes between African American (AA) and Caucasian mRCC patients tre...

Full description

Bibliographic Details
Main Authors: T. Anders Olsen, Dylan J. Martini, Subir Goyal, Yuan Liu, Sean T. Evans, Benjamin Magod, Jacqueline T. Brown, Lauren Yantorni, Greta Anne Russler, Sarah Caulfield, Jamie M. Goldman, Wayne B. Harris, Omer Kucuk, Bradley C. Carthon, Viraj A. Master, Bassel Nazha, Mehmet Asim Bilen
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-06-01
Series:Frontiers in Oncology
Subjects:
renal cell carcinoma
immunotherapy
immune-checkpoint-inhibitors
racial disparities
real-world outcomes
anti-PD-1/PD-L1
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.701345/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.701345/full

Similar Items